Skip to main content

Back to Roundups

Trump Overnight3 sources

Trump goes quiet overnight after touting Eli Lilly Pennsylvania drug plant

The president has credited the pharmaceutical company’s U.S. construction as driven by a desire to avoid tariffs.

U.S. Army photo by Bernardo Fuller

President Donald Trump on Nov. 12 shared pharmaceutical company Eli Lilly's announcement that it was "[breaking] ground in Pennsylvania's Lehigh Valley on a $3.5 billion site." The share marked his third documented social-media promotion of the drug plant. He added no comment of his own, and made no additional overnight posts.

According to a Nov. 12 press release from Sen. Dave McCormick (R-Pa.), the Fogelsville plant is expected to begin operating by 2031. McCormick's release says it is expected to create 850 “high-paying” permanent jobs and about 2,000 construction jobs.

The project is part of a capital expansion commitment Lilly announced last year, adding up to planned spending of more than $50 billion since 2020.

The latest Lilly statement also includes a statement from Pennsylvania Governor Josh Shapiro: “We secured this historic, life-changing investment thanks to Pennsylvania's world-class workforce, research institutions, infrastructure, and resources, and my Administration will continue working hard to ensure Pennsylvania remains a place where groundbreaking discoveries can translate into meaningful economic opportunities and results for patients and families.”

Trump's Truth Social post carried the company's headline and a link to its release.

Trump also promoted the plant on July 5, 2026, sharing a screenshot of a Twitter post by a conservative commentator that credited him with the investment. He also praised it in a June 23, 2026, speech at a Mack Trucks plant in Macungie, Pa.

“In the last few months alone, we've added 2,600 Pennsylvania manufacturing jobs,” he said. “And that number is going to go much, much higher as the factories start to open, because right here in Lehigh Valley, Eli Lilly has just announced … a $3.5 billion investment in a brand new state of the art manufacturing facility right down the road.”

Trump has said tariffs are why drugmakers are building at home. At a Jan. 29, 2026, Cabinet meeting, he said Lilly, Merck, Pfizer and others were "building plants in the United States because they want to be able to save a lot of money on tariffs."

Reuters reporting from early 2025 links some of the investments to tariffs on foreign ingredients necessary for drug manufacturing and pressure from the president: “Trump, who campaigned on a promise to boost domestic manufacturing, has been piling pressure on drugmakers since taking office to move medicine production to the U.S.”

Sources cited

The records behind this story are open on Sourcebase in Ask Trump.

Explore the evidence in Ask Trump on Sourcebase (opens in a new tab)

Get new stories by email

One email when Roundups publishes. No digests, no marketing, unsubscribe in one click.